Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety extension study of HB0034 in generalized pustular psoriasis
CTR20242844Phase 2Active
- Sponsor
- Shanghai Huaota Biopharmaceutical Co., Ltd.
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of HB0034 in generalized pustular psoriasis (GPP), sponsored by Shanghai Huaota Biopharmaceutical Co., Ltd.. Started Sep 2024; status: active.
02
Drugs
HB0034
03
Conditions
generalized pustular psoriasis (GPP)
Beyond the preview
Go deeper on CTR20242844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242844.